-

Purdue Pharma Statement with Respect to District Court Decision Vacating Bankruptcy Court’s Confirmation of the Plan of Reorganization

STAMFORD, Conn.--(BUSINESS WIRE)--Purdue Pharma L.P. today announced its intent to appeal today’s ruling by the United States District Court for the Southern District of New York, which vacated the Bankruptcy Court’s September 2021 order confirming its chapter 11 plan of reorganization (the “Plan”). The company will simultaneously continue its efforts to forge yet further consensus around a Plan that will deliver billions of dollars to the American people for opioid abatement. The current Plan enjoys overwhelming support, including from every one of the many ad hoc creditor groups in the case and more than 95% of Purdue’s over 120,000 voting creditors, including 43 states and territories. Fewer than 20 stakeholders appealed.

Contrary to more than 30 years of governing precedent approving third party releases in appropriate circumstances, the District Court held that third party releases are never authorized by the Bankruptcy Code outside of the asbestos context.

“While the district court decision does not affect Purdue’s rock-solid operational stability or its ability to produce its many medications safely and effectively, it will delay, and perhaps end, the ability of creditors, communities, and individuals to receive billions in value to abate the opioid crisis,” said Steve Miller, Chairman of the Purdue Pharma L.P. Board of Directors. “These funds are needed now more than ever as overdose rates hit record-highs, and we are confident that we can successfully appeal this decision and deliver desperately needed funds to the communities and individuals suffering in the midst of this crisis.”

Purdue’s Plan of Reorganization was developed through more than two years of collaborative efforts in an inclusive process that saw governments, creditors, and representatives of individual victims come together to forge a solution that serves the public interest.

Please click here for more information on Purdue’s Plan.

Contacts

Media:
Michele Sharp
(203) 588-7584

PURDUE PHARMA L.P.

Details
Headquarters: Stamford, CT
CEO: Dr. Craig Landau
Employees: 550
Organization: PRI

Release Versions

Contacts

Media:
Michele Sharp
(203) 588-7584

More News From PURDUE PHARMA L.P.

Purdue Pharma L.P. Files New Plan of Reorganization Providing for More Than $7.4 Billion in Creditor Distributions

STAMFORD, Conn.--(BUSINESS WIRE)--Purdue Pharma L.P. (“Purdue”) today filed a Chapter 11 Plan of Reorganization (the “Plan”) and related disclosure statement with the United States Bankruptcy Court for the Southern District of New York. Assuming full creditor participation, the Plan will deliver to creditors more than $7.4 billion of cash, subject to certain reserves, to compensate victims and abate the opioid crisis. There will also be substantial value created by the continued development and...

New Study Explores Nalmefene and Naloxone for Reversal of Respiratory Depression Induced by Fentanyl in a Clinical Opioid Induced Respiratory Depression Model

STAMFORD, Conn.--(BUSINESS WIRE)--Purdue Pharma L.P. (“Purdue”) today announced The Journal of Clinical Pharmacology has published findings from a study in healthy adult volunteers that demonstrated in a clinical model of opioid induced respiratory depression (OIRD), intramuscular (IM) nalmefene (1 mg) reversed fentanyl-induced respiratory depression similar to or better than IM naloxone and intranasal (IN) naloxone.1 Imbrium Therapeutics L.P. (“Imbrium”), a subsidiary of Purdue, sponsored this...

Study Examining Use of Nalmefene HCI Injection for Opioid Overdose Reversal in Emergency Departments Concludes Observational Period

STAMFORD, Conn.--(BUSINESS WIRE)--Purdue Pharma has completed the first phase of a study examining the use of nalmefene hydrochloride (HCI) injection in real-world emergency department (ED) settings. Researchers are now conducting data analysis, with study results expected later this year. The research was funded by Purdue. Nalmefene hydrochloride injection is available as a 2mg/2mL (1mg/1mL) vial, and is an opioid antagonist indicated for the complete or partial reversal of opioid drug effects...
Back to Newsroom